Gilead Sciences, Inc. Cowen analyst Phil Nadeau is out with a research note on shares of Gilead Sciences, Inc.
J.P.
Healthcare giant Gilead Sciences, Inc. (NASDAQ:GILD) is gearing up for another quarterly report after the closing bell on Wednesday.
Yesterday at the 9th International Aids Society (IAS) conference on HIV Science in Paris, Gilead Sciences, Inc. (NASDAQ:GILD) made crucial strides forward.
Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the FDA has approved VoseviTM (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, a single-tablet regimen for the …
Third party sources are saying Gilead Sciences, Inc. (NASDAQ:GILD) domestic Wholesale Acquisition Costs (WACs) of various products have seen a price boost, to …
Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency …
